Sugi Predict

Sugi Predict / Compounds / SCHEMBL1174897

SCHEMBL1174897

SCHEMBL1174897

CNC(=O)C(NC(=O)c1nc(-c2ccccc2)n2c1CN(S(=O)(=O)c1ccccc1)CC2)C(C)(C)C

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 6/20 0.68
▸ CNR1 P21554 4/20 0.46
▸ GAA P10253 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ ADAM17 P78536 2/20 0.39
▸ MMP1 P03956 1/20 0.38
▸ P2RY12 Q9H244 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1174893 1.00 CNR2 (0.68) CNR2CNR1GAAALDH1A1ADAM17
SCHEMBL1174647 0.94 CNR2 (0.63) CNR2CNR1GAAALDH1A1KMT2A
SCHEMBL1174261 0.94 CNR2 (0.63) CNR2CNR1GAAALDH1A1USP2
SCHEMBL1174263 0.94 CNR2 (0.63) CNR2CNR1GAAALDH1A1USP2
SCHEMBL1174644 0.94 CNR2 (0.63) CNR2CNR1GAAALDH1A1KMT2A
SCHEMBL1174557 0.93 CNR2 (0.61) CNR2CNR1GAAALDH1A1
SCHEMBL1174559 0.93 CNR2 (0.61) CNR2CNR1GAAALDH1A1
SCHEMBL1175173 0.92 CNR2 (0.61) CNR2CNR1ALDH1A1MMP1KMT2A
SCHEMBL1174640 0.92 CNR2 (0.61) CNR2CNR1GAAALDH1A1ADAM17
SCHEMBL1174642 0.92 CNR2 (0.61) CNR2CNR1GAAALDH1A1ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859538-B2 Uses of substituted imidazoheterocycles CARA THERAPEUTICS, INC. (US) 2014-10-14 — — US claimed
US-8859538-B2 Uses of substituted imidazoheterocycles CARA THERAPEUTICS, INC. (US) 2014-10-14 — — US disclosed
EP-2170350-B1 SUBSTITUTED IMIDAZOHETEROCYCLES CARA THERAPEUTICS INC (US) 2013-09-11 — — EP disclosed
US-8431565-B2 Substituted imidazoheterocycles CARA THERAPEUTICS, INC. (US) 2013-04-30 — — US disclosed
US-20110034443-A1 USES OF SUBSTITUTED IMIDAZOHETEROCYCLES CARA THERAPEUTICS, INC. (US) 2011-02-10 — — US disclosed
US-20090149450-A1 SUBSTITUTED IMIDAZOHETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-06-11 — — US disclosed
US-7517874-B2 Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain CARA THERAPEUTICS, INC. (US) 2009-04-14 — — US disclosed
US-20080318935-A1 SUBSTITUTED IMIDAZOHETEROCYCLES CARA THERAPEUTICS, INC. (US) 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149450-A1 SUBSTITUTED IMIDAZOHETEROCYCLES CNR1, CNR2, TRPV1 CNR2 2/4885CNR1 1/4885GAA 4090/4885
US-20110034443-A1 USES OF SUBSTITUTED IMIDAZOHETEROCYCLES CNR2, CNR1, TRPV1 CNR2 1/4885CNR1 2/4885GAA 3789/4885
US-20080318935-A1 SUBSTITUTED IMIDAZOHETEROCYCLES CNR1, CNR2, TRPV1 CNR2 2/4885CNR1 1/4885GAA 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.